Abraxis

In: English and Literature

Submitted By abraxis22
Words 444
Pages 2
University of Phoenix Material

Overview of Information Systems Table

|Information Systems Types |Description / Benefits |Example of Each (Including Vendor Name / Vendor Website) |How have you seen |
| | | |them used in your |
| | | |organization or an |
| | | |organization that you|
| | | |are familiar with? |
|Databases |is basically a collection |http://www.webopedia.com/TERM/D/database.html | |
| |of information organized |, a telephone book is an example. |I seen this used at |
| |in such a way that a | |my computer at work |
| |computer program can | |too process files and|
| |quickly select desired | |data. |
| |pieces of data. You can | | |
| |think of a database as an | | |
| |electronic filing system. |…...

Similar Documents

Biocon

...PHARMACEUTICALS: 2010 Syngene and Endo Pharma Collaboration to Develop Anti-cancer Novel Therapeutic Molecules. SYNGENE - DuPONT CROP PROTECTION: 2009 Syngene and DuPont Crop Protection Forge Alliance Partnership SYNGENE- BRISTOL-MYERS SQUIBB: 2009 Bristol-Myers Squibb and Biocon's Syngene opened new R&D Facility at Biocon Park. BIOCON- IATRICa, 2008 Partnership for the co-development of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. BIOCON- NEOPHARMA: 2007 Partnership to Manufacture and Market Biopharmaceuticals in GCC Countries. BIOCON-VACCINEX: 2004 Partnership to Discover and Develop Therapeutic Antibodies. BIOCON - PFIZER: 2012 Biocon to pursue its global Insulin’s strategy. BIOCON-ABRAXIS: 2007 Licensing agreement for G CSF in North America and the European Union & for the commercialization of ABRAXANE in India. BIOCON-FEROZSONS: 2007 Exclusive Marketing License for BIOMAb EGFR® for Pakistan. BIOCON - ISB: 2009 Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management. Growth Strategy of Biocon: Competitive Strategy: Innovation: Biocon is India's premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and......

Words: 4668 - Pages: 19

Biomab

...Bangalore

Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on biopharmaceuticals

Biocon and Abraxis BioScience, announce an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union.

Biocon and Neopharma sign an MoU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.

Biocon and Abraxis BioScience Inc., announce a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. 

Biocon presents the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam. 


2008 

Biocon acquires a 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million 

Biocon launches a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe™ and NUFIL Safe™ are the first two drugs that will be marketed using this novel device with other injectable products to follow in the future.

Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer. 

Biocon is ranked among the top 20 global biotechnology companies......

Words: 1246 - Pages: 5

Nanoparticles in Drug Targeting

...increase product lifecycle. (6)FUTURE BARRIERS AND CHALLENGES[65] * Big Pharmaceutical Companies Reluctant To Invest In Untried Technologies * Lack Of Regulatory Case Law * Long Admission Procedures Including For Example Several Clinical Trials. * Need For Rapid Screening Methods. * Scalability of nanoparticle production. * An urgent Need For Analytical Methods * The Potential Toxicity Of Engineered Nanoparticles Is Unsolved. (7)Various Nanopharmacueticals And Their Case Study According To drug Targeting[66] (7.1) CANCER THERAPY: Case Study -- Nanocarrier’s Micellar Nanoparticles And Key Delivery Systems Case Study -- Abraxis BioScience’s Nanoparticle Albumin Bound (nabTM) Technology Platform Case Study -- Abraxis BioScience’s Abraxane® Case Study -- Access Pharmaceuticals, Inc.’s Nanoparticle Aggregate Drug Delivery Technology Case Study -- Access Pharmaceuticals’ ProLindac™ Case Study -- Advance Nanotechnologies’ Nanoparticle Composites Drug Delivery System Case Study -- BioAlliance Pharma’s Nanoparticle-based Transdrug® Drug Delivery Platform Case Study -- Cornerstone Pharmaceuticals’ Emulsiphan™ Nanoparticle Tumor Targeting Technology Case Study -- Insert Therapeutics’ Nanoparticle Mediated Drug Delivery System Case Study -- Keystone Nano’s Molecular Dots (MDs) Drug Delivery Technology Case Study -- Magforce Nanotechnologies’ MagForce® Nanoparticles Case Study -- Tempo......

Words: 10751 - Pages: 44

Finanve in Banking

...ENDO PHARMACEUTICALS: 2010 Syngene and Endo Pharma Collaboration to Develop Anti-cancer Novel Therapeutic Molecules. SYNGENE - DuPONT CROP PROTECTION: 2009 Syngene and DuPont Crop Protection Forge Alliance Partnership SYNGENE- BRISTOL-MYERS SQUIBB: 2009 Bristol-Myers Squibb and Biocon's Syngene opened new R&D Facility at Biocon Park. BIOCON- IATRICa, 2008 Partnership for the co-development of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. BIOCON- NEOPHARMA: 2007 Partnership to Manufacture and Market Biopharmaceuticals in GCC Countries. BIOCON-VACCINEX: 2004 Partnership to Discover and Develop Therapeutic Antibodies. BIOCON - PFIZER: 2012 Biocon to pursue its global Insulin’s strategy. BIOCON-ABRAXIS: 2007 Licensing agreement for G CSF in North America and the European Union & for the commercialization of ABRAXANE in India. BIOCON-FEROZSONS: 2007 Exclusive Marketing License for BIOMAb EGFR® for Pakistan. BIOCON - ISB: 2009 Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management. Growth Strategy of Biocon: Competitive Strategy Innovation: Biocon is India's premier biopharma enterprise focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems......

Words: 4681 - Pages: 19

Biocon

...Research Institute | | |in Bangalore | |2007 |Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on | | |biopharmaceuticals | |2007 |Biocon and Abraxis BioScience, announce an agreement wherein Abraxis will license the right to develop a biosimilar| | |version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union. | |2007 |Biocon and Neopharma sign an MOU to establish Neobiocon, a joint venture company in Dubai's biotechnology and | | |research park, Dubiotech. | |2007 |Biocon and Abraxis BioScience Inc., announce a licensing agreement for the commercialization of ABRAXANE® | | |(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the terms of the | | |agreement, Biocon will also have the right to market ABRAXANE in Pakistan, Bangladesh, Sri Lanka, United Arab | | |Emirates, Saudi Arabia, Kuwait and certain other Persian Gulf......

Words: 2907 - Pages: 12